NCT04593121View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

March 5, 2024

Study Completion Date

March 5, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

BIIB107

Administered as specified in the treatment arm.

DRUG

Placebo

Administered as specified in the treatment arm.

Trial Locations (3)

33143

QPS MRA (Miami Research Associates), Miami

66212

Altasciences Clinical Research, Overland Park

92801

CenExel Anaheim Clinical Trials, Anaheim

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY